Two SPAC deals as the clock keeps ticking

by | May 31, 2022

Two SPAC deals today and some important votes this week.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

SPAC Deal: MAAQ + Cardio Diagnostics

Mana Capital Acquisition Corp. (MAAQ) announces a DA with Cardio Diagnostics, an “artificial intelligence-driven Integrated Genetic-Epigenetic Engine™ that enables improved diagnosis and prevention of cardiovascular disease.” Cardio Diagnostics is expected to have an approximate post-transaction equity market capitalization of $175 million assuming no redemptions, and will list on the Nasdaq as “CDIO.” Expected close in the second half of 2022. No slide deck.

SPAC Deal: GIAC+ Freightos

Gesher I Acquisition Corp. (GIAC) announces a DA with Fedex-backed Freightos. The transaction values Freightos, a digital platform for global freight booking services, at a pro forma $435M enterprise value. The transaction is expected to generate gross proceeds of at least $80 million (and up to $166 million depending on redemptions). Expected close in 2H 2022. There is an investor call tomorrow am.

GLBL – on track to close 2H 2022

Cartesian Growth Corporation (GLBL) announced it has received the required pre-closing approvals and is on track to close its merger with Tiedemann Group and Alvarium Investments in 2H 2022.

OPA / Forbes on ice

Axios notes that Forbes’ IPO plans may be in trouble. Magnum Opus Acquisition Limited(OPA), which is looking to merge with Forbes, has filed two deadline extensions so far this year.

Elsewhere in SPACs

SPAC votes this week

  • Wed: NAAC / TeleSign; RBAC / SeatGeek; BIOT / Blade
  • Thu: EDTX extension
  • Fri: SVFC / Symbotic

SPAC Calendar

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.